RxDoctor Payments Data

Joseph Neighbors, MD

Urology · Raleigh, NCNPI 1295741726

Payments from drug & device makers

$11,823in general payments, 2019–2025

Across 530 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$2K
  • Astellas Pharma US Inc$1K
  • Verathon Inc.$1K
  • Johnson & Johnson$1K
  • Myriad Genetic Laboratories, Inc.$855
  • AbbVie$563
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$1,25011%
  • Food & beverage$10,04785%
  • Education$5264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,823 in reported general payments places this provider in the 80th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$225,804
Medicare patients
454
Services billed
9,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide39$538,183
NubeqaDarolutamide22$210,341
MyrbetriqMirabegron184$160,571
GemtesaVibegron149$106,546
OrgovyxRelugolix20$51,295
Tamsulosin Hcl623$9,582
Potassium Citrate ErPotassium Citrate92$7,368
Dutasteride194$5,857
Testosterone37$4,449
Tadalafil33$3,448
Solifenacin Succinate76$2,890
Finasteride179$2,884
Silodosin25$2,286
Alfuzosin Hcl ErAlfuzosin Hcl63$1,607
Testosterone Cypionate53$1,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,340$698,754223 claims
BayerNubeqa$224$210,34122 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$494$157,841169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 urology providers in North Carolina.

Other urology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →